Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company’s vaccines and said it would cancel some contracts and stop ...

Moderna ( ($MRNA) ) has risen by 10.01%. Read on to learn why. Moderna’s stock has experienced a notable increase of 10.01% over the past week, ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Teams that bring a variety of experience and expertise can spot problems faster and arrive at more well-rounded, viable solutions. They can think beyond their own blind spots.

Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

Illinois researchers, including some working on vaccines for cancer and rare diseases, worry the federal government turning ...

With that in mind, let's consider two stocks that people in their 30s -- who are still a good distance away from retirement - ...

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy ...

The United States paid $15 to $16.50 for each shot, on top of the $1.3 billion the government gave Moderna to develop its vaccine. The European Union has paid $22.60 to $25.50 for its Moderna doses.

Moderna’s expected 400% hike for its COVID vaccine sparked outrage on Capitol Hill. The pharmaceutical giant could raise the price of the vaccine from its current $26 per dose to between $110 ...

If Canada is serious about becoming a global powerhouse in fields such as AI and life sciences then this intrapreneur mindset ...